Editorial Board
Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards in 2011, and the Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.
Dr. Cheng obtained a doctorate (PhD) in Structural Biology from the University of Science and Technology of China. Currently Dr. Cheng is a Professor in the School of Life Sciences, East China Normal Universty. He has published more than 100 papers in journals such as Nature Materials, Nature Communications, J. Am. Chem. Soc. and Angew. Chem. Int. Ed. Dr. Cheng is currently the Editorial Board Member of Letters in Drug Design & Discovery, and the guest editor of Topics in Current Chemistry. His research focused on drug and gene delivery systems.
Martin Braddock is a professional scientist and project manager working in the field of drug discovery and development with 32 years experience of working in academic institutes Universities of Dundee and Oxford) and large corporate organisations. He holds a BSc in Biochemistry and a PhD in Radiation Biology (both from the University of Salford) and is a former Royal Society University Research Fellow at the University of Oxford. His current role is Global Products Manager and Global Alliance Manager for Tralokinumab, an anti-IL-13 monoclonal antibody for the treatment of patients with severe asthma presently undergoing phase III clinical trials.
Prof. Bazylak received Ph.D. in Food Chemistry from the Technical University, Lodz, Poland and D.Sc. (habilitation) in Pharmacy from the Medical University, Gdansk, Poland. He served as post-doc in the Medical University of Lodz (Poland) and the University of Antwerp (Belgium). He is working from 2004 as the Associate Professor and Head of Pharmaco-Bromatology and Molecular Nutrition at the Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland. He has published more than 150 scientific publications, edited the 12 special topic issues of international scholary journals and is now engaged in the jury of the 20th edition of the Annual Pharmacy Professor’s Award in Poland.
Detlev Boison, PhD, is the Vice Chair of Research and Training and Professor, RWJMS & NJMS Neurosurgery Department Rutgers, The State University of New Jersey School of Public Health Bldg. Dr. Boison has a passion for translational research and for finding cures for intractable conditions that cause human suffrage and death. He translates fundamental mechanisms of biochemistry and energy metabolism into novel therapeutic approaches for the treatment of neurological conditions. A major research effort is the development of metabolism-based therapies that enable disease modification in epilepsy and after traumatic brain injury. He graduated from the University of Köln, Germany, in 1994 with a PhD in Biochemistry. In 2005, he received the venia legend (Habilitation) in Cellular Pharmacology from the University of Zurich, Switzerland, for his work on cell-based adenosine augmentation therapies for epilepsy. Over the past 25 years he maintained a rigorous research program on translational adenosine research and has continuously funded NIH since 2008. His research interest is in Neurology, The adenosine hypothesis of schizophrenia, Role of adenosine in cancer and Metabolic therapies etc. He has published over 190 papers with an h-index of 62 and has delivered over 150 invited lectures worldwide.
Dr. A. Semalty did his M. Pharm. (Pharmaceutics), MBA (Operations Management); Ph. D., PDF from Meijo University, Japan. He has academic and research experience of 15 years with 1 year Industrial Experience. He completed 8 research projects funded by various agencies. He published 73 papers, 6 books, 2 patents, presented papers in more than 100 conferences; Highly cited researcher of the field (h index 22), Awarded with the prestigious national Research Award by UGC, New Delhi; Developed two SWAYAM massive open online courses (MOOCs) on Academic Writing and Industrial Pharmacy for open learning; Creating awareness for open education resources for academics through delivering expert lectures, developing cyclodextrin nanoparticles and SANS.
Dr. Abdul Ahad is an Assistant Professor at Department of Pharmaceutics, College of Pharmacy, King Saud University Riyadh, Saudi Arabia. Dr. Ahad did his Master and Doctorate in Pharmaceutical Sciences from Department of Pharmaceutics, Jamia Hamdard, New Delhi, India. He has published various high quality research and review articles in several peer-reviewed journals of international repute. He is on Editorial Board of several Pharmaceutical journals and reviewer of many peer-reviewed journals. His current interest lies in Nanotechnology products for dermal/transdermal drug delivery and lipid based formulations.
Javed Ahmad, Ph.D., is an Assistant professor at Department of Pharmaceutics, College of Pharmacy, Najran University, Kingdom of Saudi Arabia (KSA). He received his Doctorate degree in pharmaceutical sciences from School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi (India). He is a recipient of several awards, including International Travel Award/Grant and CSIR-Senior Research Fellowship from Department of Science & Technology, Govt. of India. He has published various high quality research and review articles in peer-reviewed journals of international repute. He is reviewer of many peer-reviewed journals of Pharmaceutical Sciences. His current research interest lies in nanotechnology-mediated drug delivery and development of lipid-based nanomedicine.
Alex Aronov received his PhD in bioorganic chemistry from the University of Washington in 1998. He completed his postdoctoral training at UCSF, working on structure-based design and synthesis of novel anti-parasitics, and holds an MBA from MIT Sloan. He started his industrial career in molecular modeling at Vertex Pharmaceuticals in Cambridge, MA. From 2007 to 2012, he led a cross-functional team to deliver a novel immuno-oncology therapy BVD-723. He is currently Director and Head, Early Discovery Modeling & Informatics at Vertex, with responsibility for global Modeling & Informatics support of Vertex’s early discovery efforts. He is an author of 30 peer-reviewed manuscripts, and is an inventor on over 40 international patent applications
Dr. Behraven received a Pharm.D. degree from Mashhad University of Medical Sciences (MUMS) and a Ph.D. from the University of Sheffield UK. His current position is Professor and head of the Biotechnology Research Center at MUMS. He is a member of Editorial board of a number of international journals and have more than 120 International paper publications.
Marco Bonesi graduated cum laude in Chemistry and Pharmaceutical Technology at the Faculty of Pharmacy of the University of Calabria (Italy). He received his Ph.D. (2002-2006) “Biochimica e Patologia dell’Azione dei Farmaci” (IV Ciclo – Nuova serie) in co-tutorship with the University René Descartes, Paris (France). Research interests include the development of analytical strategies for extraction, isolation, structural characterization and the in vitro evaluation of biological activities of phytochemicals from medicinal plants and plant foods. Investigations are focused on the determination of anti-proliferative activity against human tumour cell lines, hypoglycaemic, antioxidant, antihypertensive, and neuroprotective properties.
Dr. Bramham is head of the Neuroscience Research Group and partner in KG Jebsen Centre for Neuropsychiatric Disorders at the University of Bergen, Norway. Research in Dr. Bramham’s lab aims to elucidate the cell biological and molecular mechanisms that control synaptic plasticity in the brain, and the dysregulation of these mechanisms in cognitive disorders. Dr. Bramham has published more than 100 research papers and book chapters.
Vito Calderone is an assistant professor at the Department of Chemistry in the University of Florence. He has been involved in structural biology since his PhD. In particular, his main expertise is the structural determination of proteins of biological interest through x-ray crystallography. His main research topics include structural determination of mytochondrial proteins and metalloproteins (mainly involved in electron transfer processes and in metal trafficking in the cell), application of X-ray crystallography in structure-based drug design and structural studies of metal-mediated protein–protein complexes.
Dr. Caulfield is a trained chemist from Georgia Tech, whom has a faculty position at the Mayo Clinic working in the field of drug screening and drug design. Dr. Caulfield has past training at UCSD, Roche and TPIMS in nanotechnologies, drug development and advanced chemistry design techniques for screening drug candidates with novel targets. At Mayo Clinic, Dr. Caulfield functions to accelerate drug discovery efforts across a swath of disciplines.
Dr. Rita Cortesi obtained her doctorate (Ph.D.) in Pharmaceutical Sciences from the University of Ferrara, Italy. She attended a HMC Post-doc fellowship at Pharmaceutical Sciences Department of Nottingham University (U.K.). Currently Dr. Cortesi is an Associate Professor at the Department of Life Sciences and Biotechnology of Ferrara University. She has published more than 120 scientific publications considering papers on international journal, book’s chapters and patents. Dr. Cortesi currently belongs to the Editorial Board of this journal (Current Drug Discovery Technologies, CDDT), published by Bentham Science Publishers.
Dr. Degterev is an Associate Professor at the Department of Developmental, Molecular and Chemical Biology at Tufts University. His work focuses on the analysis of the mechanisms and development of the small molecule modulators of cell death processes that contribute to human pathologies. Dr. Degterev pursues multidisciplinary studies combining cell and chemical biology, and animal pharmacology. Dr. Alexei Degterev earned M.S. in Chemistry from Moscow State University, Russia and Ph.D. in Biochemistry from Boston University School of Medicine, MA. Upon graduation, he joined the laboratory of Dr. Junying Yuan in the Department of Biology of Harvard Medical School as a post-doctoral fellow and, subsequently, as Instructor in Cell Biology. Since November 2005, Dr. Degterev is an Assistant Professor of Biochemistry at Tufts University. Dr. Degterev is a recipient of the Mentored Career Development Award from the National Institute on Aging, Alzheimer’s Research Pilot Award from the American Health Assistance Foundation and Smith Family Award for Excellence in Biomedical Research from the Massachusetts Medical Foundation. Dr. Degterev is the author of multiple patents and more than 60 scientific publications.
Dr. Deng is a faculty member engaged in cancer research and has held the appointment of associate professor in the Department of Radiation Oncology at Emory University School of Medicine. Dr. Deng completed his postdoctoral training at the University of Texas Medical Branch. Major research interests are to develop novel small molecule anti-cancer agents and new therapeutic strategies for cancer therapy by targeting apoptosis and DNA repair signaling pathways. He has published more than 87 scientific publications and is a named inventor of 3 issued U.S patents.
Prof Dondas received his Ph.D. degree in 1997 from University of Leeds, UK under the supervision of Professor Ronald Grigg and received Best Ph.D. Thesis award. In 1997 he was appointed Assistant Professor and become Associate Professor in 2001 at Mersin University. Since March 2007, he has been promoted to full Professor at Mersin University Faculty of Pharmacy. He worked as a Post-Doctoral Research Fellow (2000–2001) at University of Leeds (UK) with Professor Ronald Grigg and Post-Doctoral Research Fellow (2004) at University of Ghent, Faculty of Bioscience Engineering Ghent-Belgium with Professor Norbert De Kimpe. He has also worked as Visiting Researcher in 1998, Visiting Scholar in 2003 and 2005 at the University of Leeds.He was invited Visiting Research Scientist at the University of Leeds in 2008, 2015, 2017 and 2017 and asVisiting Research Scientist at University of Alicante-Spain (2018).
Dr. Giovanni Di Fabio graduated in Chemistry at the University of Napoli, FEDERICO II. In 1998, he received the PhD under the supervision of Prof. Lorenzo De Napoli, working on nucleic acids chemistry. His work includes organic synthesis and characterization of natural and modified ODNs; Solid Phase Synthesis and biophysical characterization of modified ODNs forming G-quadruplex endowed with anti-HIV activity; Synthesis of novel modified metabolites (nucleosides/tides, flavonoids/lignans) with pharmacological activity (antiviral, anticancer, neuroprotective agents). Recently he worked on the quali- and quantitative analysis of metabolites in nutraceuticals and functional foods.
Adilson Kleber Ferreira is presently the principal investigator in the department of Immunology at the Biomedical Science Institute. He accomplished his Ph.D. research in the area of developments of new anticancer drugs at the Faculty of Medicine of the University of Sao Paulo in Brazil. Ferreira completed his Ph.D. in Oncology from Frank`s Laboratory at the University of Groningen Netherlands. He studied the molecular effects of new drugs candidate against non-small cell lung cancer. He also completed his training with a one-year post-doctoral fellowship in the University Medical Center Groningen, Netherlands - Research Institute for Drug Exploration of Department of Oncology. He also did postdoctoral research at the department of Immunology, aimed for the development and validation of new anticancer compounds for lung cancer treatment.
Professor Ana Rita Figueiras has obtained her Ph.D degree from the University of Coimbra, and is a Researcher and Assistant Professor in the Faculty of Pharmacy in this institution. Actually, Ana Figueiras is a scientific member of REQUIMTE/LAQV. Her research areas are polymeric micelles, cyclodextrins and mucoadhesive polymers in drug delivery. During her Ph.D thesis she acquired experience in drug permeability, cellular viability and cytotoxicity studies, mucoadhesive biomaterials, therapeutic applications of cyclodextrins and computational studies in drug design. Now, her objective is to combine know-how development during her Ph.D thesis and new strategies for successful drug delivery.
Dr. Ge received his Ph.D degree in 2009 from Dalian Institute of Chemical Physics, Chinese Academy of Sciences. Following eight-year working at Dalian Institute of Chemical Physics, CAS, Dr. Ge joined in Shanghai University of Traditional Chinese Medicine as a full professor and vice dean of Institute of Interdisciplinary Medicine in 2017. His current studies are focused on the development of new techniques or bioanalytical methods for drugs and drug targets, as well as the applications of these techniques in drug discovery. Now he is the author/coauthor of more than 130 publications in scientific journals, with the H-index of 23.
Professor Stefano Giovagnoli is an Associate Professor in Pharmaceutical Technology and Biotechnology at the Department of Pharmaceutical Sciences, University of Perugia, Italy. His main research interests focus on dry powders for the treatment of pulmonary infections, organic and inorganic nanoparticles for targeted and local delivery and the engineering of cells as drug delivery systems and therapeutic tools. He serves as board member of the Journal of Pharmaceutical Innovation and the Journal of Medicinal Chemistry and Research, Review Editor of Frontiers in Pharmacology. He is member of the AAPS, the Italian Chemical Society (SCI), the AAPS Italian University Network (AItUN), the Association of Italian Faculties of Pharmaceutical Technology and Regulation (ADRITELF) the Italian CRS chapter and the Aerosol Society.
Daniele Giuffrida obtained his Ph D at the University of Shefffield (England) in 1994. He is currently an Associate Professor of Food Chemistry, at the University of Messina, Italy. He currently teaches the course of "Natural Product Chemistry and Nutraceutical" in the degree course in Food Sciences, at Messina University. He is the author of more then 200 publications and three book chapters.
Giuseppina Ioele is an Assistant Professor in Pharmaceutical Chemistry, at the University of Calabria. The research activity is focused in the field of the analytical pharmaceutical chemistry, particularly in the design of photo-stabilizing pharmaceutical systems applied on photosensitive drugs and in the development of advanced methods for the analysis of multicomponent pharmaceutical systems and for the quality assurance of drugs. The design of photostabilizing pharmaceutical systems is applied on antihypertensives of the 1,4-dihydropyridinic series and on anti-inflammatory drugs as diclofenac, to improve the stability of liquid and semisolid formulations, respectively.
Josef Jampilek completed his Ph.D. degree in Medicinal Chemistry at the Faculty of Pharmacy of the Charles University (Czech Republic) in 2004. From 2004-2011, he worked at managerial posts in the R&D Division of the pharmaceutical company Zentiva (Czech Republic).. In 2009, he became an Associate Professor of Medicinal Chemistry at the Faculty of Pharmacy of the University of Veterinary and Pharmaceutical Sciences Brno (Czech Republic). In 2017, he became a Full Professor of Medicinal Chemistry at the Faculty of Pharmacy of the Comenius University (Slovakia). He is an author/co- author of more than 30 patents/patent applications, more than 180 peer-reviewed scientific publications, 7 university textbooks, 20 chapters in monographs, and many invited lectures at international conferences and workshops. He also received several awards for his scientific results, e.g., from Aventis, Elsevier, Willey, Sanofi and FDA. The research interests of Prof. Jampilek include design, synthesis, and structure-activity relationships of heterocyclic compounds as anti-infectious and antiproliferative agents as well as photosynthesis inhibitors. He is also interested in ADME and drug bioavailability.
Dr. Snehasis Jana has more than 15 years of new drug discovery and development research experience in various Indian pharmaceutical industries. He holds a basic degree in Pharmaceutical Sciences, a PhD in Molecular mechanisms of Drug Resistance Mechanisms (Molecular Pharmacology & Biotechnology) from Dept. of Biochemical Engg. & Biotechnology, IIT-Delhi, India and has extensive drug discovery & developmental research experience in various therapeutic targets at Ranbaxy, BMS-Biocon Research Center, Sai Life Science & Laila Nutraceuticals. He is an expert for establishing strategic directions for preclinical/clinical nutra/pharmaceuticals discovery research focused on Anticancer, Chemopreventive agents, Probiotics/prebiotics, hepatoprotective, anti-infective, anti-inflammatory, arthritis, Cardiovascular, anti-aging, obesity, diabetes, Cognition & Memory, and Overall health etc. Dr. Jana's publication record exceeds 45 research articles and reviews.
Beginning his career as a synthetic chemist, Terry Kenakin received a Ph.D. in Pharmacology at the University of Alberta, Edmonton Canada. After a post-doctoral Fellowship at University College London, U.K., he joined Burroughs-Wellcome as an associate Scientist. From there he continued working in drug discovery at Glaxo Inc.,GlaxoWellcome and finally GlaxoSmithKline. Leaving his position as a Director at GlaxoSmithKline Research and Development laboratories at Research Triangle Park, N.C. USA, Dr. Kenakin is now a professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill. Currently he is engaged in studies aimed at the optimal design of drug activity assays systems, the discovery and testing of allosteric molecules for therapeutic application and the quantitative modeling of drug effects. In addition, he is Director of the Pharmacology curriculum at the UNC School of Medicine. He is a member of numerous editorial boards as well as Editor in Chief of the Journal of Receptors and Signal Transduction and Co-editor in Chief of Current Opinion in Pharmacology. He has authored numerous articles and has written 10 books on Pharmacology.
Prashant Kesharwani is currently working as a Ramanujan Fellow (Scientist-D)at CSIR-Central Drug Research Institute (CDRI), Lucknow, India. He received his PhD in pharmaceutical sciences from the Dr H.S. Gour University (Sagar, India) within the group of N.K. Jain. He is a recipient of several internationally acclaimed awards, including a Ramanujan Fellowship, DST, India (2017), Excellence Research Award (2014), Young Innovator Award (Gold medal; 2012), International Travel Award/Grant from DST (New Delhi), and INSA (CCSTDS, Chennai) (2012). He received a ICMR Senior Research Fellowship (for his PhD) and an AICTE Junior Research Fellowship (for his M. Pharm.).
Gert (H. G.) Kruger graduated from Potchefstroom University, South Africa, in 1996 under the supervision of Frans (F. J. C.) Martins and Attie (A. M.) Viljoen. His Ph.D. lineage is traced back to Rudolf Criegee (Wutzburg) via Johan Dekker (Karlsruhe). The Dekkers introduced cage chemistry to South Africa, and Kruger actively pursues the design, computational chemistry, synthesis, and biotesting of new drugs in the Catalysis and Peptide Research Unit at UKZN.
Dr. Luqman is engaged in Research and Development commotion of bioactivity prospection group at CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow where his team is working on the discovery of natural products and new biologically active compounds/molecules from Medicinal and Aromatic Plants (MAPs) for their anti-infectious and anticancer activity. He is a scientist (CSIR-CIMAP) and assistant professor (AcSIR) at Lucknow, Uttar Pradesh, India. He has a number of scientific publications to his credit.
Dr. Uttam Kumar Mandal is as an Associate Professor at Department of Pharmaceutical Sciences & Technology, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Punjab, India. He has 9 years of teaching experience (out of which 5 years in IIUM, Malaysia), 10 years of research experience (out of which two years as Post-doctoral Fellow at University of Geneva, Switzerland). His research interest includes drug delivery, development of transdermal nanoformulations (transfersomes, ethosomes, niosomes), solubility enhancement, modern analytical techniques, bioavailability & bioequivalence. Based on his diverse fields of research experiences, he has published more than sixty research papers in various high impact factor journals.
Dr. Mattheakis is currently Vice President of Biology at Protagonist Therapeutics. His nearly 25 years of experience in biotech R&D includes developing novel technologies for drug screening and leading preclinical programs in oncology and immune disorders. He is the author of numerous publications and inventor on key patents. Dr. Mattheakis received a Ph.D. in Biochemistry from the University of Wisconsin-Madison, and trained as a post-doctoral research fellow in the Department of Microbiology and Molecular Genetics at Harvard Medical School. He is a member of Faculty of 1000 in Chemical Biology, and serves as an editor for the Journal of Biomolecular Screening (SLAS Discovery).
Dr. Mattia Mori obtained his degree in Medicinal Chemistry and his PhD in Structural Biology from the University of Florence, Italy. Currently, he is a researcher at the Center for Life Nano Science at Sapienza of the Istituto Italiano di Tecnologia (IIT) in Roma, Italy. The research activity of Dr. Mori focuses on medicinal chemistry and drug discovery, with a particular dedication to the use of computer simulations to discover and develop bioactive small molecules, or to study the conformational space of target proteins. Dr. Mori is a co-author of more than 45 papers and 1 patent.
Dr. Claudio Nastruzzi obtained his Ph.D. degree (in 1988) in Pharmaceutical Science from University of Ferrara (Department of Pharmaceutical Science), Ferrara, Italy. Dr. Nastruzzi is currently serving as an Associate Professor in the Department of Life Sciences and Biotechnology at University of Ferrara. His skills and expertise include Biomaterials, Nanoparticles, Nanotechnology, Tissue, Engineering, Pharmaceutical Development, Composite Material, Microfluidics, Cell Differentiation, Controlled Drug Delivery, Nanotechnology in Drug Delivery, Nutraceuticals, Liposomes, Encapsulation Micelles, Supramolecular Chemistry, etc. Dr. Nastruzzi, as an author/co-author, has published more than 200 articles in various journals, having a significant number of total citations, i.e. over 3,845.
Dr. O’Bryan is an Associate Professor of Pharmacology at the University of Illinois at Chicago. He obtained his PhD from the University of North Carolina at Chapel. He has more than 25 years experience in the area of signaling transduction, adaptor proteins, and kinase signaling and has published more than 50 manuscripts and reviews in these areas. In addition to maintaining an active research group, Dr. O’Bryan serves as Co-Director of the Graduate Education in Medical Science (GEMS) Program at UIC, which is responsible for the education and training of PhD candidates in the College of Medicine at UIC. Dr. O’Bryan also holds a joint appointment as a Research Biologist at the Jesse Brown VA Medical Center in Chicago, IL.
Dr. Gennady Poda is Principal Research Scientist and Manager, Computational Chemistry and Chemoinformatics at the Ontario Institute for Cancer Research and Assistant Professor (status only) at the Leslie Dan Faculty of Pharmacy, University of Toronto, Canada. He obtained a Master of Science degree in Molecular and Chemical Physics at the renowned Moscow Institute of Physics and Technology (MIPT) and a PhD in Bioorganic Chemistry from the Institute for Bioorganic and Petrochemistry, National Academy of Sciences in Kyiv, Ukraine. During his prominent work at Pharmacia & Upjohn, Pfizer and now OICR he demonstrated excellence in computer-aided drug design covering all aspects of modern computational drug discovery: structure-, ligand- and fragment-based drug discovery, chemoinformatics, medicinal chemistry, data mining and analysis, physical and ADMET property prediction, methods development and programming. He is a co-author of 57 publications, 3 book chapters and 7 patents.
Dr. Root earned a PhD from the Molecular Biology Institute at the University of California, Los Angeles. Dr. Root currently designs and synthesizes small molecule modulators of muscle force generation based on structural and functional studies of protein interactions using spectroscopic and single molecule assays, several of which were developed in his laboratory. In addition, Dr. Root has directed courses in Biochemistry at the University of North Texas for 20 years.
Dr. Maria Cristina De Rosa graduated in Chemistry at the University Sapienza of Rome, Italy and, for three years, she was a CNR fellow.She was visiting researcher at the Department of Biotechnology, chemistry and pharmacy of the University of Siena, Italy and visiting researcher at the Laboratory of Molecular Biophysics, University of Oxford-UK.Since 1997 she is CNR Researcher at the Institute of Chemistry of Molecular Recognition (ICRM) SS ofRome, where she leads the molecular modelling team.Her scientific activity focuses on structural characterization of target proteins and rational drug design using in silico methods.
Dr. Ruvo graduated in Chemistry at the University of Naples in 1991. He spent the first 10 years of his career as industrial researcher (Tecnogen, Italy), working as head of the protein and peptide laboratory and contributing at the development of several bioactive peptides. In 2002, he joined the Institute of Biostructures and Bioimaging of the National Research Council (IBB-CNR) in Naples, working as senior scientist and leading several projects focused on the development of new bioactive peptides and monoclonal antibodies against targets with a role in cancers development. Among the others, he has developed peptides modulating the activity of PlGF, Cripto, and Gadd45β and mAbs against Nodal, the E2 protein of HCV and Cripto. He is also the scientific founder of Kesios Therapeutics Ltd (London). He is author of about 100 papers and inventor of >10 patents.
Dr. Shubhini A. Saraf is a Professor and Director (R&D) is working in the Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University. She is an M.Pharm., Ph.D. and Ex Head (Dept. of Pharm. Sciences), Ex Dean, School of Biomedical and Pharmaceutical Sciences and Ex-Dean of School of Biosciences & Biotechnology. Her field of expertise is Pharmaceutics. She did Ph.D. from Dr. H.S. Gaur University, Sagar (M.P.) India in the Development, Characterisation and Evaluation of Stimuli Sensitive Polymer Based Hypodermal Systems of Some Drugs. She has been involved in a number of projects and published around 164 articles, besides she has filed two patents and has presented a number of conference proceedings. She is a board member of a number of journals such as Current Drug Discovery Technologies, International Journal of Science Technology and Society, A.P.T.I. Women's Newsletter: Editor 2019-22 and Guest Editor of Current Pharmaceutical Design published by Bentham Science. She is a registered pharmacist with U. P. Pharmacy Council, member of Academic council' (07-08) and (10-11), member 'Board of Studies' for B. Pharm. & M. Pharm. and member of 'Examination committee' of G. B. Technical University, Lucknow. (formerly U.P.T.U., now A.K.T.U.). She received a number of awards, such as Academic excellence award for 3 consecutive years as director of Pharmacy program, B.B.D.N.I.T.M., by U.P.T.U.; Senior scientist award 2012, Indian Medicos Society; Travel grant from Royal Society of Chemistry, London, 2012; etc.
Dipak Sarker is an Associate Professor of Pharmaceutics. He graduated with a PhD in physics in 1995, and is a nanotechnologist and material scientist working in the fields of industrial product science and medical devices and drug delivery. He has a number of doctoral students and postdoctoral scientists in his interfacial nanoscience group and links with other institutions and industrial organisations.
She graduated in Pharmacy and Hospitality Medicine Specialization both at the University of Naples in 1980 and 1982. In 1989 he obtained the DEA in Pharmacologie et Pharmacochimie at Louis Pasteur I University in Strasbourg . In 1990 he obtained his doctorate in Pharmaceutical Sciences from the University of Naples. From 1991 to 1993 he worked at the UFR des Sciences Pharmaceutiques of the University of Caen. From 1993 to 2000 he was a University Researcher of the University of Salerno. From 2001 to 2016 he was Associate Professor of the Faculty of Pharmacy of the University of Salerno.
Dr. Sil is currently working as a Research Instructor at Buffet Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, USA in the department of Pharmaceutical Sciences. In May 2019, he joined UNMC as a Postdoctoral Research Associate in Dr. David Oupicky’s laboratory. Prior to joining UNMC, he was a Postdoctoral Fellow in the Department of Medicinal Chemistry at the University of Kansas from 2006 to 2011. Thereafter, he became a Research Associate in the same university from 2011 to 2014. Subsequently, he worked as a Joint Manager at Atul Ltd., Gujarat, India from 2015 to 2019 in the area of process development of important pharmaceutical intermediates. He has twenty-eight publications in peer reviewed journals including a book chapter and a US patent.
Alexander S. Sobolev, completed his PhD in 1972, and D.Sc. (Biol.) in 1983. He became the full professor of Biophysics of Moscow State University, Faculty of Biology, Head of Department of Molecular Genetics of Intracellular Transport of the Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia. He remained an honored scientist of the Russian Federation and a distinguished Professor of the Moscow State University. He is anactive Member of the American Association for Cancer Research, American Society of Gene and Cell Therapy and some other scientific societies. His main scientific interests are in the field of subcellular targeted delivery of anti-cancer agents (e.g. radionuclides emitting short-range particles, photosensitizers), bioactive substances and genetic material.
Dr. Torrens obtained a doctorate (Ph.D.) in Physical Chemistry from the Universitat de València, Spain. Currently Dr. Torrens is Lecturer in Physical Chemistry in the Universitat de València. His scientific accomplishments include the first implementation in a computer at the Universitat de València of a program for the elucidation of crystallographic structures and the construction of the first computational-chemistry program adapted to a vector-facility supercomputer in a Spanish university. He has published 2 books, 370 articles and 1672 presentations. He has been Advisor of 4 Ph.D. and 1 M.Sc.
Dr. Marco Tutone received his Ph.D. degree in pharmaceutical sciences in 2006. From 2006 to 2008, he was a Post-doc research fellow at the University of Palermo. In October 2019, he became an associate professor of medicinal chemistry at the University of Palermo. His research activity focuses on computational medicinal chemistry. In recent years, he has also been focusing on the study of natural substances along with the design, synthesis and biological evaluation of dopaminergic modulators. Since 2014, he has been involved in the study of TRIDs and he is also the owner of an international patent.
Melgardt de Villiers is Professor and Associate Dean at the School of Pharmacy - University of Wisconsin. His research focuses on developing innovative nano and micro particulate drug delivery systems. He is the author of 150 peer reviewed publications and book chapters and has presented his research at meetings more than 200 times. He has supervised 17 PhD and 21 MS students. In 2005 he was the Outstanding Professor in the College of Health Sciences at the University of Louisiana at Monroe and in 2012 he was elected as a fellow of the American Association of Pharmaceutical Scientists (AAPS).
Paul Wender received his PhD from Yale University, was an NIH Fellow at Columbia University, served on the faculty at Harvard University and is currently the Bergstrom Professor of Chemistry and Professor of Chemical and Systems Biology at Stanford University. He serves on several internal and external advisory board and has founded various companies based on his research. His work is described in >300 publications and >20 issued or pending patents. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Association of Arts and Sciences, and the Royal Spanish Academy of Sciences. His work has been recognized with numerous awards, including more recently the 2015 Stanford Office of Technology Licensing Innovator Award, 2015 Israel Chemical Society Cohen Award for Excellence in Medicinal Chemistry, 2015 ACS Cope Award, and the 2016 Research Award of the German Bioactives and Biotechnology Leibniz Alliance.
Dr. Peisheng Xu is an Associate Professor of Pharmaceutical Sciences in the Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, at the University of South Carolina. His research foci include targeted drug delivery, nanomedicine, and environmental sensitive pharmaceutical nanocarriers for cancer and CNS diseases therapy. He has published more than 30 original papers and book chapters, and holds 10 US granted patents. He was an New Investigator Award recipient from the American Association of College of Pharmacy (AACP).
Dr. Dharmendra Kumar Yadav obtained a Ph.D. in Biomedical Sciences from CSIR- Central Institute of Medicinal and Aromatic Plants, Lucknow, India in 2013. Currently, he is working as a Research Professor and Principal Investigator of NRF project (Korea) at College of Pharmacy at Gachon University, Korea. His research interests included Molecular modeling & Drug Design, and Molecular simulation of Plasma Medicine. He has published more than 45 original and review papers and three scientific books chapter one US patent. He is the Editor and Editorial Board Member of the many journals.
Sho-ichi Yamagishi is a Professor and Chairman, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan. He has graduated from Kanazawa University School of Medicine, Japan and became a medical doctor in 1989. He has received a PhD from Kanazawa University, Japan in 1993. He received Basic Science Award "Angiogenesis Stem Cell Award" from American Heart Association in 2003 and "Distinguished Investigator Award from Japan Diabetes Society in 2005. He is serving as an editorial board member in 20 reputed journals and published more than 550 research papers, including Nature, JCI, and Diabetes, etc. His research fields are Diabetes, Cardiology and Gerontology.
Dr. Zhang obtained B. Eng. in Biochemical Engineering at Huaqiao University, China, 1986. After eight years of teaching and research in Biochemical Engineering at the Zhejiang University of Technology, he went to University of Leeds as a Ph.D. student to study in Microbiology. He joined Linhardt Group at University of Iowa in 1999, after he worked in Hong Kong University of Science and Technology (HKUST) for one year. He moved to Rensselaer Polytechnic Institute (RPI) as a research faculty in 2003. His research areas are glycomics and glycobiology. He has published more than 200 research papers and several patents.
Dr. Zheng is University Professor and Chief, Division of Cancer Pharmacology, Rutgers University, and Co-leader, Cancer Pharmacology Program at the NCI-Designated Comprehensive Cancer Center Consortium of Rutgers and Princeton Universities. Dr. Zheng received his PhD degree and postdoctoral training at Harvard University. His long-standing research interest is mTOR signaling in growth and metabolism regulation, and the role in cancer biology and therapeutic targeting. He made major contributions to the mTOR field, including demonstration of TOR as the physiological target of rapamycin and elucidation of the mechanism of rapamycin action, and discovery of many key components and functions of TOR pathway.
Dr. Zhou is a tenured Professor in the Chemical Biology Program at University of Texas Medical Branch (UTMB). He was educated and trained from Nankai University, University of Virginia, and Georgetown University Medical Center, respectively. He has over 20 years of research experience in drug discovery and development including 7 years of industrial experience in pharmaceuticals. His research interest is developing novel small molecules as valuable chemical probes and potential therapeutics for central nervous system disorders, cancer/inflammation, and infectious diseases. He has published more than 100 peer-reviewed journal papers, 6 book chapters, and 15 patents.
Dr. Zulli’s research focus is on the detrimental effects of homocysteine on vascular function, studying the RAS and NOS. This extends to interests in the stress systems, including ER stress and nitrative stress. He uses pharmacological approaches, as well as immunohistochemistry and histolpathological methods.
Sajjad Gharaghani received his Ph.D. in Chemoinformatics from Isfahan University of Technology, Isfahan (Iran). Then, joined with department of bioinformatics, Institute of Biochemistry and Biophysics (IBB) in 2013 and founded the Laboratory of Bioinformatics and Drug Design http://LBD.ut.ac.ir at the University of Tehran. His research interest includes: Computer-Aided Drug Design (CADD), Bioinformatics, Chemoinformatics, Pharmacoinformatics, Systems Pharmacology, Chemogenomics, Biological Networks, QSAR, Fragment-based drug design, Molecular Docking, Molecular Dynamics Simulation, Drug Targets Interaction, Statistical techniques, Machine Learning, etc.
